{"id":743799,"date":"2013-06-02T10:15:00","date_gmt":"2013-06-02T10:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/"},"modified":"2023-03-22T00:04:36","modified_gmt":"2023-03-22T04:04:36","slug":"merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/","title":{"rendered":"Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013"},"content":{"rendered":"<p class=\"bwalignc\">       Merck Expands Lambrolizumab Clinical Development Program-     <\/p>\n<p class=\"bwalignc\">       Study Published Online in the New England Journal of Medicine-     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of preliminary results from an ongoing<br \/>\n      Phase IB expansion study evaluating the safety and efficacy of<br \/>\n      lambrolizumab (MK-3475), Merck\u2019s investigational antibody therapy<br \/>\n      targeting PD-1, in patients with advanced (inoperable and metastatic)<br \/>\n      melanoma. The data were presented by Antoni Ribas, M.D., Ph.D.,<br \/>\n      professor, Hematology\/Oncology and Surgery, and director of the Tumor<br \/>\n      Immunology Program at the Jonsson Comprehensive Cancer Center,<br \/>\n      University of California, Los Angeles, during an oral session at the<br \/>\n      American Society of Clinical Oncology (ASCO) 2013 Annual Meeting in<br \/>\n      Chicago (Abstract# 9009). The study was also published online in the <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nejm.org&amp;esheet=50644451&amp;lan=en-US&amp;anchor=New+England+Journal+of+Medicine&amp;index=1&amp;md5=a0acbb8ce80b648b6e397ac1bac8ae70\"><i>New<br \/>\n      England Journal of Medicine<\/i><\/a>.\n    <\/p>\n<p>\n      \u201cWe are encouraged by the results observed to date, including the rate<br \/>\n      and duration of responses, in patients with advanced melanoma,\u201d said<br \/>\n      Roger M. Perlmutter, M.D. Ph.D., president, Merck Research Laboratories.<br \/>\n      \u201cBased on these data and additional findings from our ongoing studies,<br \/>\n      Merck plans to initiate late-stage clinical trials of lambrolizumab in<br \/>\n      advanced melanoma, and non-small cell lung cancer in the third quarter<br \/>\n      of 2013.\u201d\n    <\/p>\n<p>\n      Data from the ongoing multi-center, single-arm open-label Phase IB trial<br \/>\n      were presented from 135 patients with advanced melanoma enrolled in the<br \/>\n      study and who were administered an initial dose of lambrolizumab between<br \/>\n      Dec. 1, 2011, and Sept. 6, 2012. Patients received one of three dosing<br \/>\n      regimens of lambrolizumab (10mg\/kg every two weeks [10mg\/kg Q2W];<br \/>\n      10mg\/kg every three weeks [10mg\/kg Q3W] or 2mg\/kg every three weeks<br \/>\n      [2mg\/kg Q3W]) until disease progression or unacceptable toxicity. Tumor<br \/>\n      response was assessed every 12 weeks by independent, central, blinded<br \/>\n      radiographic review per RECIST 1.1 (Response Evaluation Criteria in<br \/>\n      Solid Tumors) criteria as well as investigator-assessed, immune-related<br \/>\n      response criteria. Earlier interim data from this study were presented<br \/>\n      at the <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fpress-release%2Fresearch-and-development-news%2Fmerck-presents-early-stage-interim-data-mk-3475-investig&amp;esheet=50644451&amp;lan=en-US&amp;anchor=9th+International+Congress+of+the+Society+for+Melanoma+Research+%28SMR%29&amp;index=2&amp;md5=2a799dbddbbc0dc245d096c667009e64\">9th<br \/>\n      International Congress of the Society for Melanoma Research (SMR)<\/a> in<br \/>\n      Hollywood, Calif., in November 2012.\n    <\/p>\n<p>\n      <b>Objective response rates for lambrolizumab in patients with advanced<br \/>\n      melanoma<\/b>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\" rowspan=\"2\">\n          Dose\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">\n            irRC Investigator<br \/>Assessment\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"5\">\n          RECIST 1.1 Independent Review\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          N\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <sup>1<\/sup>ORR %<br \/>(95% CI)\n          <\/p>\n<p class=\"bwcellpmargin\">&nbsp;<\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          N\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Response<br \/>Duration<br \/>(mths)\n          <\/p>\n<p class=\"bwcellpmargin\">&nbsp;<\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <sup>1<\/sup>ORR %<br \/>(95% CI)\n          <\/p>\n<p class=\"bwcellpmargin\">&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          10mg\/kg Q2W\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          57\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          56 (42-69)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          52\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          1.9+-10.8+\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          52 (38-66)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          10mg\/kg Q3W\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          56\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          27 (16-40)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          45\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          2.6 -8.3+\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          27 (15-42)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          2mg\/kg Q3W\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          22\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          14 (3-35)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          20\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          2.1+-5.5+\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          25 (9-49)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Total\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          135\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          37 (29-45)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          117\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          1.9+-10.8+\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          38 (25-44)\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          <sup>1<\/sup> Objective response rate = confirmed complete response<br \/>\n          (CR) and partial response (PR)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      The interim overall confirmed response rate for lambrolizumab treatment<br \/>\n      was 38 percent (range 25\u201344 percent), as measured by RECIST 1.1<br \/>\n      independent review across all dosing regimens evaluated. The highest<br \/>\n      overall response rate observed was 52 percent, which occurred in the 10<br \/>\n      mg\/kg Q2W dosing regimen. Ten percent of patients in this dose group<br \/>\n      were complete responders. The duration of confirmed responses, as<br \/>\n      measured after the first 12 week evaluation, ranged from greater than 28<br \/>\n      days to up to more than 8 months at the time of the analysis, with 80<br \/>\n      percent of responding patients continuing on treatment. The median<br \/>\n      duration of response has not been reached with a median follow-up time<br \/>\n      of 11 months. The most common treatment-related adverse events observed<br \/>\n      for those patients evaluable for adverse events, as of December 2012,<br \/>\n      were mostly grade 1\/2 and included fatigue (30%), rash (21%), pruritus<br \/>\n      (21%) and diarrhea (20%). Six (4.4%) treatment-related cases of<br \/>\n      pneumonitis were reported (all grade 1\/2). A total of 17 (13%) grade 3\/4<br \/>\n      treatment-related adverse events were reported, the most common of these<br \/>\n      were fatigue (1.5%), rash (2%) and elevated AST levels (1.5%). The<br \/>\n      majority of reported grade 3\/4 events occurred in patients administered<br \/>\n      10mg\/kg Q2W.\n    <\/p>\n<p>\n      The response rates for ipilimumab-pretreated and ipilimumab-na\u00efve<br \/>\n      patients treated with lambrolizumab were similar.\n    <\/p>\n<p>\n      \u201cWe continue to make significant progress in our clinical development<br \/>\n      program for lambrolizumab in multiple indications,\u201d said Gary Gilliland,<br \/>\n      M.D., Ph.D., senior vice president and oncology franchise head, Merck<br \/>\n      Research Laboratories. \u201cWe are very grateful to the patients,<br \/>\n      investigators, regulators and the broader oncology community for their<br \/>\n      ongoing collaboration and support in advancing this program.\u201d\n    <\/p>\n<p>\n      <b>Lambrolizumab Clinical Development Program<\/b>\n    <\/p>\n<p>\n      Merck is currently conducting four clinical trials evaluating<br \/>\n      lambrolizumab in multiple cancer types that involve more than 600<br \/>\n      patients. The company recently initiated a global, randomized, Phase II<br \/>\n      clinical trial of lambrolizumab versus standard chemotherapy for<br \/>\n      patients with advanced melanoma whose disease has progressed after prior<br \/>\n      therapy (ref: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01704287%3Fterm%3DNCT01704287%26rank%3D1&amp;esheet=50644451&amp;lan=en-US&amp;anchor=NCT01704287&amp;index=3&amp;md5=265166043389c245ac2b9306fc1b5144\">NCT01704287<\/a>)<br \/>\n      and a Phase I trial of lambrolizumab for the treatment of triple<br \/>\n      negative breast, metastatic bladder cancer and head &amp; neck cancer (ref: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01848834%3Fterm%3Dmk-3475%26rank%3D3&amp;esheet=50644451&amp;lan=en-US&amp;anchor=NCT01848834&amp;index=4&amp;md5=69161f44a258df05ed4411714b299acd\">NCT01848834<\/a>).<br \/>\n      Further late-stage studies including a Phase III study evaluating<br \/>\n      lambrolizumab in ipilimumab-na\u00efve patients with advanced melanoma and a<br \/>\n      Phase II\/III trial in non-small cell lung cancer (NSCLC) are scheduled<br \/>\n      to commence in the third quarter of 2013. Additional trials in several<br \/>\n      hematological cancers and evaluation of lambrolizumab-containing<br \/>\n      combinations are scheduled to start this year. Merck announced that <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fpress-release%2Fresearch-and-development-news%2Fmerck-announces-breakthrough-therapy-designation-lambrol&amp;esheet=50644451&amp;lan=en-US&amp;anchor=lambrolizumab+had+received+Breakthrough+Therapy+designation&amp;index=5&amp;md5=6da73249ab64783187f24355e46e6d5a\">lambrolizumab<br \/>\n      had received Breakthrough Therapy designation<\/a> from the U.S. Food and<br \/>\n      Drug Administration for advanced melanoma in April 2013.\n    <\/p>\n<p>\n      <b>Merck Oncology Briefing Webcast<\/b>\n    <\/p>\n<p>\n      Merck will hold a briefing on June 2 at 1:00 p.m. CDT to present an<br \/>\n      update of ongoing progress in the development of its oncology candidates<br \/>\n      MK-1775 and vintafolide, as well as provide details regarding its<br \/>\n      clinical development plans for lambrolizumab. Investors&nbsp;and journalists<br \/>\n      may access a live audio webcast of the event on Merck\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Finvestors%2Fevents-and-presentations%2Fhome.html&amp;esheet=50644451&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Finvestors%2Fevents-and-presentations%2Fhome.html&amp;index=6&amp;md5=737f83239d6fc1d48cf1edb960aaacc7\">http:\/\/vip2-msd.com\/merckcom-migrated\/investors\/events-and-presentations\/home.html<\/a>.<br \/>\n      Software needed to listen to the webcast is available on the corporate<br \/>\n      website and should be downloaded prior to the beginning of the webcast.<br \/>\n      A replay of the webcast will be available at approximately 8:00 a.m. EDT<br \/>\n      on June 3.\n    <\/p>\n<p>\n      <b>About Lambrolizumab<\/b>\n    <\/p>\n<p>\n      Lambrolizumab is an investigational antibody therapy designed to disrupt<br \/>\n      the action of the immune checkpoint protein PD-1 and therefore inhibit<br \/>\n      the ability of some cancers to evade the body\u2019s immune system.<br \/>\n      Lambrolizumab is being studied in multiple cancer types including<br \/>\n      melanoma and non-small cell lung cancer. For further details, please<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DMK-3475%26Search%3DSearch&amp;esheet=50644451&amp;lan=en-US&amp;anchor=http%3A%2F%2Fclinicaltrials.gov&amp;index=7&amp;md5=e39db457a8e17c5b9b6693e7de3d5b47\">http:\/\/clinicaltrials.gov<\/a>.\n    <\/p>\n<p>\n      <b>About Breakthrough Therapy Designation<\/b>\n    <\/p>\n<p>\n      The designation of an investigational drug as a Breakthrough Therapy is<br \/>\n      intended to expedite the development and review of a candidate that is<br \/>\n      planned for use, alone or in combination, to treat a serious or<br \/>\n      life-threatening disease or condition when preliminary clinical evidence<br \/>\n      indicates that the drug may demonstrate substantial improvement over<br \/>\n      existing therapies on one or more clinically significant endpoints. The<br \/>\n      Food and Drug Administration Safety and Innovation Act (FDASIA) includes<br \/>\n      a provision that allows sponsors to request that an investigational drug<br \/>\n      be designated as a Breakthrough Therapy. The implications of<br \/>\n      Breakthrough Therapy Designation cannot be determined at this time.\n    <\/p>\n<p>\n      <b>About PD-1<\/b>\n    <\/p>\n<p>\n      Researchers have shown that several tumor types are able to hide in<br \/>\n      plain sight by establishing a \u201cmolecular camouflage\u201d that deceives the<br \/>\n      body\u2019s immune system into thinking they are normal and therefore allow<br \/>\n      them to grow unchecked. The interaction between the immune checkpoint<br \/>\n      receptor PD-1 and its ligands represents a potentially important<br \/>\n      tumor-specific immunomodulatory mechanism. By utilizing the PD-1<br \/>\n      pathway, a tumor cell can prevent the activation of T-cells and<br \/>\n      therefore may block a key step that triggers the immune system.\n    <\/p>\n<p>\n      <b>About Advanced Melanoma<\/b>\n    <\/p>\n<p>\n      Advanced melanoma accounts for more than 80 percent of skin<br \/>\n      cancer-related deaths and one to two percent of all cancer deaths in the<br \/>\n      United States. According to the American Cancer Society, an estimated<br \/>\n      9,180 people in the U.S. died from advanced melanoma in 2012.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50644451&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=8&amp;md5=c06c232c6afe61e7712128c07508ecf1\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=50644451&amp;lan=en-US&amp;anchor=Twitter&amp;index=9&amp;md5=3e3985fa7caceb2fc483969120694fa3\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50644451&amp;lan=en-US&amp;anchor=Facebook&amp;index=10&amp;md5=b962d256bc6f63c37da0c3f0ade6294b\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50644451&amp;lan=en-US&amp;anchor=YouTube&amp;index=11&amp;md5=b2ff3075fd04cace5767bcd10e5e5490\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50644451&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=12&amp;md5=0a216c128b67db5af20ef8125bdf929f\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130602005049r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Ian McConnell, 973-901-5722<br \/>Cathy        Cantone, 908-327-3013<br \/>or<br \/>Investor Contacts:<br \/>Carol        Ferguson, 908-500-1101<br \/>Justin Holko, 609-915-8293     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Expands Lambrolizumab Clinical Development Program- Study Published Online in the New England Journal of Medicine- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab (MK-3475), Merck\u2019s investigational antibody therapy targeting PD-1, in patients with advanced (inoperable and metastatic) melanoma. The data were presented by Antoni Ribas, M.D., Ph.D., professor, Hematology\/Oncology and Surgery, and director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, during an oral session at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting in Chicago (Abstract# 9009). The study was also published online in the New England Journal of Medicine . \u201cWe are encouraged by the results observed to date, including the rate and duration of responses, in<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-743799","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck Expands Lambrolizumab Clinical Development Program- Study Published Online in the New England Journal of Medicine- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab (MK-3475), Merck\u2019s investigational antibody therapy targeting PD-1, in patients with advanced (inoperable and metastatic) melanoma. The data were presented by Antoni Ribas, M.D., Ph.D., professor, Hematology\/Oncology and Surgery, and director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, during an oral session at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting in Chicago (Abstract# 9009). The study was also published online in the New England Journal of Medicine . \u201cWe are encouraged by the results observed to date, including the rate and duration of responses, in\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:36+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130602005049r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\\\/\",\"name\":\"Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130602005049r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2013-06-02T10:15:00+00:00\",\"dateModified\":\"2023-03-22T04:04:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130602005049r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130602005049r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013 - Merck.com","og_description":"Merck Expands Lambrolizumab Clinical Development Program- Study Published Online in the New England Journal of Medicine- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab (MK-3475), Merck\u2019s investigational antibody therapy targeting PD-1, in patients with advanced (inoperable and metastatic) melanoma. The data were presented by Antoni Ribas, M.D., Ph.D., professor, Hematology\/Oncology and Surgery, and director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, during an oral session at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting in Chicago (Abstract# 9009). The study was also published online in the New England Journal of Medicine . \u201cWe are encouraged by the results observed to date, including the rate and duration of responses, in","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:36+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130602005049r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/","name":"Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130602005049r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2013-06-02T10:15:00+00:00","dateModified":"2023-03-22T04:04:36+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130602005049r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130602005049r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentation-of-interim-data-from-study-evaluating-lambrolizumab-an-investigational-anti-pd-1-antibody-in-patients-with-advanced-melanoma-at-asco-2013\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"c3bac1aa-00a0-4f1a-a32a-0569ec5353bc","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Presentation-of-Interim-Data-from-Study-Evaluating-Lambrolizumab-an-Investigational-Anti-PD-1-Antibody-in-Patients-wi-3HE6N.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743799\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743799"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}